Pasithea Therapeutics Set to Shine at The CAGLA Conference

Author: Addison Perry Updated: 03-24-2025 07:00 AM

Pasithea Therapeutics to Present at Premier Oncology Conference

MIAMI — Pasithea Therapeutics Corp. (NASDAQ: KTTA), a clinical-stage biotechnology company, is gearing up to make a significant impact at an upcoming oncology event. During the renowned Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference, scheduled for March 27-29, 2025, our Vice President of Business Development, Mathew Lazarus, will showcase the latest advancements in our pioneering research.

Highlighting Innovative Treatments

At this conference, Mr. Lazarus is expected to delve into PAS-004, an advanced macrocyclic MEK inhibitor designed to treat neurofibromatosis type 1 (NF1) and additional types of cancer. His presentation will spotlight interim safety, tolerability, and pharmacokinetic (PK) data gathered from our ongoing open-label dose escalation Phase 1 study. This study focuses on patients with MAPK pathway-driven advanced tumors, illustrating how our innovative approach is setting the stage for potential breakthroughs in cancer treatment.

A Closer Look at PAS-004

PAS-004 represents a promising step forward in addressing the significant challenges associated with NF1 and other malignancies. As we continue to develop this next-generation molecule, we aim to transform the landscape of treatment options available for patients who currently have limited effective therapies. Mr. Lazarus' insights into the latest clinical development progress will shed light on our commitment to advancing treatment solutions for the oncology community.

Conference Details

The CAGLA NeauxCancer Conference stands as a premier event bringing together top researchers, industry leaders, and healthcare professionals dedicated to advancing cancer treatment. With a focus on groundbreaking developments, this gathering provides a valuable platform for collaboration and sharing innovative ideas. The key details for the presentation are outlined below:

Event: 2025 CAGLA NeauxCancer Conference
Date: March 28, 2025
Time: 11:00 AM CDT
Location: The Roosevelt Hotel, New Orleans
Webcast: CAGLA 2025 Livestreams

About Pasithea Therapeutics Corp.

Pasithea Therapeutics is at the forefront of biotechnology, dedicated to the discovery and development of cutting-edge treatments for central nervous system (CNS) disorders and RASopathies. Our team comprises industry experts specializing in neuroscience, translational medicine, and drug development. We pride ourselves on our innovative approach, focusing on creating new molecular entities to combat neurological disorders such as NF1, Solid Tumors, and Amyotrophic Lateral Sclerosis (ALS). If you're interested in learning more about our work, please visit our official website.www.pasithea.com.

Get in Touch

For any inquiries regarding our participation in the conference or more information about our research, please reach out to:

Patrick Gaynes
Corporate Communications
pgaynes@pasithea.com

Frequently Asked Questions

What is the focus of Pasithea Therapeutics?

Pasithea Therapeutics specializes in developing innovative biotech solutions for CNS disorders and RASopathies.

What will Mathew Lazarus discuss at the conference?

He will present insights on PAS-004 and its effects on treating NF1 and other cancers, highlighting key clinical data.

Why is the CAGLA NeauxCancer Conference significant?

This conference is a gathering of leading professionals in oncology, showcasing the newest advancements in cancer research.

When is the CAGLA conference taking place?

The conference will occur from March 27 to 29, 2025, with Pasithea’s presentation set for March 28 at 11:00 AM CDT.

How can I contact Pasithea Therapeutics?

For questions or further information, you can contact Patrick Gaynes via email at pgaynes@pasithea.com.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.